Clinical trials: Prostate-Specific Antigen, open to volunteers
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer…
- Trial name
- TulmiSTAR-02 (NCT07190300)
- Testing
- Tulmimetostat, Darolutamide, Abiraterone
- Where
- 31 sites in United States, Australia and 12 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
This prospective, single-center diagnostic accuracy study will compare mpMRI and PSMA-PET for the detection of clinically significant prostate cancer in patients with prostate imaging reporting and data System (PI-RADS) ≥4…
- Trial name
- PRIME-TZ (NCT07892378)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI), 18F-PSMA-1007 PET, Prostate Biopsy
- Where
- Argentina
- Volunteers
- 65 people
- Sponsor
- Sanatorio Privado San Geronimo
Prostate Cancer
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance.
- Trial name
- NCT06600698
- Testing
- INM176
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Milton S. Hershey Medical Center
Metastatic Prostate Cancer
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
- Trial name
- PROSPECTOR (NCT07590934)
- Testing
- AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Prostate Cancer, Recurrent Prostate Cancer
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression in patients with prostate cancer belonging to the intermediate unfavorable or high risk group, who have low…
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent
- Trial name
- NCT07593079
- Testing
- Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Safety and Efficacy of OTL78
This is a trial to assess the accuracy of an imaging agent, PSMA targeted fluorescent dye OTL78 (zopocianine), in combination with Near InfraRed (NIR) fluorescent imaging, to improve the detection of malignant (growing in an…
- Trial name
- NCT07725523
- Testing
- 0.06 mg/kg ZOPOCIANINE given 1-7 days prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Clinton Bahler
Prostatic Neoplasms
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the…
- Trial name
- NCT07082920
- Testing
- JNJ-78278343, JNJ-95298177, JNJ-87189401
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer Patients Undergoing Radical Prostatectomy
PSMA-Targeted Intraoperative Fluorescent Imaging Agents (DGPR1008): Validation Across Different Time Windows
a Phase II, single-arm, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and the effectiveness of near-infrared fluorescence imaging during surgery.
- Trial name
- DGPR1008-04 (NCT07387510)
- Testing
- 12 h before RP, 24 h before RP, 36 h before RP
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Haitao Niu, MD
Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- PAnTHA (NCT06217822)
- Testing
- 225Ac-PSMA-Trillium (BAY3563254)
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer
A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs
The goal of this randomized comparative study (a study where participants are placed into groups by chance) is to find out if reducing treatment to androgen deprivation therapy (ADT)-a treatment that lowers testosterone-by itself…
- Trial name
- STEPDOWNmHSPC (NCT07838753)
- Testing
- De-escalation strategy, Continuation of initial Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitor (ARPI) combination therapy at standard doses
- Where
- India
- Volunteers
- 170 people
- Sponsor
- Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute
Oligometastatic Prostate Cancer (OMPC)
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary…
- Trial name
- PSMA-DC (NCT05939414)
- Testing
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial…
- Trial name
- Visioning III (NCT07762911)
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate
PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE
This observational study was designed to evaluate progression free survival after PSMA-PET/CT based salvage approach for patients affected by biochemical relapse after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate, Prostate Adenocarcinoma, Prostate Cancer Recurrent
- Trial name
- PSICHE (NCT05022914)
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Prostate Cancer
Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening
The project will investigate the efficacy of a Veteran-peer-navigator-led decision coaching (PDC) program to promote Shared Decision Making (SDM) for prostate cancer screening among Veterans at the Veterans Health Administration…
- Trial name
- NCT06549036
- Testing
- Veteran Peer Decision Coaching Session for PSA Screening
- Where
- United States
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Prostate Cancer
A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
A Phase I/IIa clinical trial to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of INR102 injection in patients with prostate cancer.
- Trial name
- NCT06970119
- Testing
- INR102 injection
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd
Advanced Prostate Cancer
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease…
- Trial name
- NCT06335914
- Testing
- Ga 68 PSMA-11 PET, 18F-DCFPyL PET, FDG PET
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer (Post Prostatectomy), Prostate Cancer (Adenocarcinoma)
Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer.
- Conditions
- Prostate Cancer (Post Prostatectomy), Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Specific Antigen
- Trial name
- PPSARP (NCT07516886)
- Testing
- Radical Prostatectomy
- Where
- Lithuania
- Volunteers
- 500 people
- Sponsor
- Lithuanian University of Health Sciences
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T
This study is a phase I dose escalation clinical trial aims to evaluate 161Tb-PSMA-I\&T, a new generation prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) using Terbium-161 to replace Lutetium-177, its…
- Trial name
- NCT07621692
- Testing
- 161Tb-PSMA-I&T
- Where
- 2 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
- Trial name
- NCT07569926
- Testing
- fluciclovine (18F)
- Where
- 6 sites in United States
- Volunteers
- 142 people
- Sponsor
- Blue Earth Diagnostics